Legal investigation launched into Sarepta Therapeutics over gene therapy deaths

NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026, A legal investigation has been launched into Sarepta Therapeutics, Inc., a biopharmaceutical company focused on rare diseases, following a series of deaths linked to its gene therapy, ELEVIDYS. The investigation, initiated by Kahn Swick & Foti, LLC (KSF), is examining whether the company's officers and directors may have breached their fiduciary duties to shareholders or violated laws.

Sarepta, based in New Haven, Connecticut, has faced scrutiny over its claims regarding the safety of ELEVIDYS. The therapy is designed to treat Duchenne muscular dystrophy. In March 2025, the company announced the death of a 16-year-old patient from acute liver failure after receiving ELEVIDYS, yet assured investors that the treatment's benefits outweighed its risks. Later that year, on June 15, Sarepta disclosed that a second patient had died from the same condition, and the company suspended shipments and paused dosing in an ongoing clinical trial. A third patient, treated with a related investigational therapy, also died from acute liver failure in June 2025, according to the company's disclosure.

Following these incidents, Sarepta and certain executives were sued in a securities class action lawsuit. The suit accuses the company and its executives of failing to disclose material information during the class period, violating federal securities laws. The lawsuit, which is ongoing, highlights the severity of the company's actions and the concerns of investors.

KSF's investigation is centered on whether Sarepta's leadership team misled investors or failed to properly disclose the risks associated with ELEVIDYS. The law firm is seeking information that could help in its legal proceedings and is urging long-term shareholders to contact them for legal advice.

KSF, founded by former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's leading boutique securities litigation firms. The firm's focus on corporate fraud and malfeasance has earned it recognition as one of the top 10 plaintiff law firms in the United States.

KSF Managing Partner Lewis Kahn stated, "Our investigation will determine whether Sarepta and its executives acted in the best interests of their shareholders or if they engaged in practices that put investors at risk."

The investigation into Sarepta Therapeutics is part of a broader scrutiny of the biopharmaceutical industry, particularly in light of recent high-profile incidents involving potential safety issues in gene therapies. As the investigation progresses, it could have significant implications for Sarepta and the broader market.